Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome
European Journal of Endocrinology · 2023
DOI: 10.1093/ejendo/lvad084 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Endocrinology, 2023. Verfasst von Demi J Trueba-Timmermans und 6 weiteren Autor:innen. Beteiligte Einrichtung: Dutch Reference Center for Prader-Willi Syndrome, 3016 AH Rotterdam, The Netherlands. Hauptthemen laut MEDLINE: Prader-Willi Syndrome, Human Growth Hormone. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Context
Most patients with Prader–Willi syndrome (PWS) have mild to moderate cognitive impairment. Growth hormone (GH) treatment has positive short- and long-term effects on cognition in children with PWS. Few studies, however, have investigated the effects of GH on cognitive functioning in adults with PWS.
Objective
To investigate the effects of 3 years of GH treatment on cognitive functioning and behavior in young adults with PWS who were treated with GH during childhood.
Design
Open-label, prospective study.
Setting
Dutch PWS Reference Center.
Methods
Patients were treated with 0.33 mg GH/m²/day (∼0.012 mg/kg/day; 33% of childhood dose). Cognitive functioning was measured by Wechsler Adult Intelligence (WAIS) tests. Behavior was studied by a developmental behavior checklist—parents/caregivers (DBC-P).
Results
Forty-six young adults with PWS with a median age of 19 (IQR 17-21) years were investigated. Estimated mean (95% CI) total, verbal, and performance IQ remained stable during 3 years of GH-treatment. Total IQ being 66 (63-69) at the start and 67 (64-71) after 3 years (P = .30); Verbal IQ being 65 (62-68) and 66 (62-70), respectively (P = .31) and performance IQ being 67 (63-70) and 67 (63-72) resp. (P = .42). Estimated mean Total DBC score did not significantly change during 3 years of GH-treatment, being 36.3 at start and 36.5 after 3 years (P = .94) (P50).
Conclusions
Three years of GH-treatment in young adults with PWS with 33% of the pediatric dose, maintains total, verbal, and performance IQ. The emotional and behavioral disturbances remained stable and were similar compared to peers with other intellectual disabilities.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Dutch Reference Center for Prader-Willi Syndrome, 3016 AH Rotterdam, The Netherlands.
- Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands.
- Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.
- Department of Pediatrics, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.
- Department of Pediatrics, Leiden University Medical Center-Willem-Alexander Children's Hospital, 2333 ZA Leiden, The Netherlands.
ORCID-Profile: Demi J Trueba-Timmermans, Anita C S Hokken-Koelega
Förderung
- Pfizer
Zitieren
APA
Trueba-Timmermans, D. J., Grootjen, L. N., Juriaans, A. F., Mahabier, E. F., Kerkhof, G. F., Rings, E. H. H. M., & Hokken-Koelega, A. C. S. (2023). Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome. European Journal of Endocrinology. https://doi.org/10.1093/ejendo/lvad084
Vancouver
Trueba-Timmermans DJ, Grootjen LN, Juriaans AF, Mahabier EF, Kerkhof GF, Rings EHHM, et al. Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome. European Journal of Endocrinology. 2023. doi:10.1093/ejendo/lvad084
BibTeX
@article{TruebaTimmermans2023,
author = {Trueba-Timmermans, Demi J and Grootjen, Lionne N and Juriaans, Alicia F and Mahabier, Eva F and Kerkhof, Gerthe F and Rings, Edmond H H M and Hokken-Koelega, Anita C S},
title = {Cognitive function during 3 years of growth hormone in previously growth hormone-treated young adults with Prader–Willi syndrome},
journal = {European Journal of Endocrinology},
year = {2023},
doi = {10.1093/ejendo/lvad084}
}
EUVIMED